PMID- 36201088
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221010
IS  - 2520-8934 (Electronic)
IS  - 2520-8934 (Linking)
VI  - 5
IP  - 1
DP  - 2022 Oct 6
TI  - Clinical outcome of drug-coated balloons in patients with femoropopliteal chronic 
      total occlusive lesions: results from the multicenter EAGLE study.
PG  - 51
LID - 10.1186/s42155-022-00329-8 [doi]
LID - 51
AB  - BACKGROUND: Several studies have reported the efficacy of drug-coated balloons 
      (DCB) for simple femoropopliteal (FP) lesions. However, the effectiveness of DCB 
      for FP chronic total occlusive lesions (CTO) is controversial. The present study 
      investigated the clinical outcomes of DCB for FP-CTO. MATERIALS AND METHODS: We 
      retrospectively analyzed 359 limbs of 318 patients who underwent endovascular 
      therapy with DCB for FP-CTO between July 2017 and February 2021 at seven 
      cardiovascular centers. The primary endpoint was 12-month primary patency. The 
      secondary endpoints were the 12-month rates of freedom from: (1) 
      clinically-driven target lesion revascularization (CD-TLR), and (2) re-occlusion. 
      The association of baseline characteristics with the 12-month restenosis risk was 
      investigated using the Cox proportional hazards regression model. RESULTS: The 
      12-month rate of primary patency was 79.8% (95% confidence interval [95%CI], 
      75.1% to 84.8%), whereas the corresponding rates of freedom from CD-TLR and 
      re-occlusion were 86.4% (95%CI: 82.6% to 90.4%) and 88.5% (95%CI: 84.7% to 
      92.4%), respectively. The bailout stent rate was 8.9%. Independent risk factors 
      for restenosis were hemodialysis (adjusted hazard ratio, 2.18 [1.39 to 3.45]; 
      P = 0.001), chronic limb-threatening ischemia (CLTI) (2.02 [1.33 to 3.07]; 
      P = 0.001), and restenosis lesion (2.02 [1.32 to 3.08]; P = 0.001). Use of dual 
      antiplatelet therapy (DAPT) was identified as a protective factor for restenosis 
      (0.54 [0.35 to 0.82]; P = 0.003). CONCLUSIONS: Despite the low rate of bailout 
      stent, DCB treatment for FP-CTO was effective in real-world clinical practice. 
      Hemodialysis, CLTI, and restenosis lesion were independent risk factors for 
      12-month restenosis, and the use of DAPT significantly attenuated the risk of 
      12-month restenosis.
CI  - (c) 2022. The Author(s).
FAU - Hayakawa, Naoki
AU  - Hayakawa N
AUID- ORCID: 0000-0002-4168-2808
AD  - Department of Cardiovascular Medicine, Asahi General Hospital, I-1326 Asahi, 
      Chiba, 289-2511, Japan. haya.naoki1981@gmail.com.
FAU - Takahara, Mitsuyoshi
AU  - Takahara M
AD  - Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 
      Osaka, Japan.
FAU - Nakama, Tatsuya
AU  - Nakama T
AD  - Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
AD  - Division of Vascular Surgery, Department of Surgery, Jikei University School of 
      Medicine, Tokyo, Japan.
FAU - Horie, Kazunori
AU  - Horie K
AD  - Department of Cardiovascular Medicine, Sendai Kousei Hospital, Sendai, Japan.
FAU - Takanashi, Keisuke
AU  - Takanashi K
AD  - Department of Cardiovascular Medicine, Asahi General Hospital, I-1326 Asahi, 
      Chiba, 289-2511, Japan.
FAU - Kanagami, Teruaki
AU  - Kanagami T
AD  - Department of Cardiovascular Medicine, Asahi General Hospital, I-1326 Asahi, 
      Chiba, 289-2511, Japan.
FAU - Ichihara, Shinya
AU  - Ichihara S
AD  - Department of Cardiovascular Medicine, Asahi General Hospital, I-1326 Asahi, 
      Chiba, 289-2511, Japan.
FAU - Arakawa, Masataka
AU  - Arakawa M
AD  - Department of Cardiovascular Medicine, Asahi General Hospital, I-1326 Asahi, 
      Chiba, 289-2511, Japan.
FAU - Tobita, Kazuki
AU  - Tobita K
AD  - Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan.
FAU - Mori, Shinsuke
AU  - Mori S
AD  - Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, 
      Japan.
FAU - Iwata, Yo
AU  - Iwata Y
AD  - Department of Cardiology, Funabashi Municipal Medical Center, Funabashi, Japan.
FAU - Suzuki, Kenji
AU  - Suzuki K
AD  - Department of Cardiology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
FAU - Kanda, Junji
AU  - Kanda J
AD  - Department of Cardiovascular Medicine, Asahi General Hospital, I-1326 Asahi, 
      Chiba, 289-2511, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221006
PL  - Switzerland
TA  - CVIR Endovasc
JT  - CVIR endovascular
JID - 101738484
PMC - PMC9537392
OTO - NOTNLM
OT  - Chronic total occlusive lesion
OT  - Drug-coated balloon
OT  - Endovascular therapy
OT  - Femoropopliteal occlusive disease
COIS- TN is a consultant of Boston Scientific, BD, Cordis, Century Medical Inc., COOK 
      Medical, Kaneka Medix, NIPRO, OrbusNeichi, Medtronic, and TERUMO Corporation. KS 
      received remuneration for lectures from Boston Scientific Japan, and consultant 
      fees from Medtronic. KT is a consultant of Gore and received a speakers fee from 
      Medtronic. The other authors report no conflicts of interest.
EDAT- 2022/10/07 06:00
MHDA- 2022/10/07 06:01
PMCR- 2022/10/06
CRDT- 2022/10/06 11:16
PHST- 2022/07/05 00:00 [received]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2022/10/06 11:16 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/07 06:01 [medline]
PHST- 2022/10/06 00:00 [pmc-release]
AID - 10.1186/s42155-022-00329-8 [pii]
AID - 329 [pii]
AID - 10.1186/s42155-022-00329-8 [doi]
PST - epublish
SO  - CVIR Endovasc. 2022 Oct 6;5(1):51. doi: 10.1186/s42155-022-00329-8.